Abstract
AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.
METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.
RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).
CONCLUSION: The Manchester Bowel Obstruction Score may aide treatment stratification.
| Original language | English |
|---|---|
| Pages (from-to) | 513-521 |
| Number of pages | 9 |
| Journal | Future Oncology |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Mar 2017 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Disease Management
- Female
- Humans
- Intestinal Obstruction/diagnosis
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Staging
- Ovarian Neoplasms/complications
- Proportional Hazards Models
- Retrospective Studies
- Treatment Outcome
